COVID-19 vaccine maker Moderna is suing Pfizer and German drug maker BioNTech, accusing its competition of copying Moderna’s generation to make its own vaccine.
Moderna said Friday that Pfizer and BioNTech’s Comirnaty vaccine infringes patents Moderna filed several years ago to protect the generation of its preventive vaccine, Spikevax. The Massachusetts-based company has filed patent infringement lawsuits in u. S. federal court. U. S. and a German court.
A Pfizer spokeswoman declined to comment, saying the company had won a copy of the dispute.
Both Moderna’s two-dose and Pfizer’s vaccines use mRNA generation for patients to fight the coronavirus.
mRNA vaccines work by injecting a genetic code for the spike protein that covers the surface of the coronavirus. This code, the mRNA, is encased in a small ball of fat and asks the body’s cells to make copies of innocent spikes that exert the immune formula for the genuine virus.
This technique is radically different from the vaccines that have historically been made.
Moderna said it began developing its mRNA generation platform in 2010, which helped the company temporarily produce its COVID-19 vaccine after the pandemic hit in early 2020.
By the end of that year, U. S. regulators were able to do so. The U. S. Food and Drug Administration allowed the use of Pfizer and Moderna injections after it was clinically proven that either was highly effective.
Moderna CEO Stéphane Bancel said in a list that the vaccine’s developer pioneered the generation and invested billions of dollars in its creation.
The company said it believes its rivals’ vaccine infringes modern patents filed between 2010 and 2016.
Moderna said it recognizes the importance of the vaccine and is not looking to take Comirnaty off the market. He also doesn’t seek a court order to save long-term sales.
Did you know that we published an Arabic edition of The Times of Israel?And a Persian edition for Iranian readers?Why we do it is at the heart of The Times of Israel’s mission. . .
That’s why we introduced The Times of Israel ten years ago, to provide discerning readers like you with a detailed policy of Israel and the Jewish world.
So now we have a request. Unlike other media outlets, we have not established a paywall. But because the journalism we do is expensive, we invite readers for whom The Times of Israel has become vital to help our paintings join the Times of Israel community.
For just $6 a month, you can help our quality journalism while enjoying The Times of Israel WITHOUT ADVERTISING, as well as access exclusive content only for members of the Times of Israel community.
Thank you, David Horovitz, founding editor of The Times of Israel.